fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Highlights from ESMO 2019

Written by | 22 Nov 2019

For the second time this year, LungCancer.Med headed to Barcelona for the Annual European Society for Medical Oncology (ESMO) meeting.  Written by Christine Clark

CAR-T cells and bi-specific agents

Written by | 11 Nov 2019

Developing CAR-T cells that are effective in solid tumours is challenging but experience in Hodgkin Lymphoma could pave the way for CAR-T cells in lung cancer. Bi-specific T-cell… read more.

Modifying the gut microbiome and personalised anti-tumour vaccines

Written by | 11 Nov 2019

Tumours use a variety of mechanisms to escape the host immune system and overcoming these to increase response rates and improve quality of life are key goals. Manipulation… read more.

Targetable mutations key learnings

Written by | 11 Nov 2019

Targeted treatments for mutation-driven non-small cell lung cancer have advanced considerably but many questions remain about how to use these drugs to the best advantage and how to… read more.

Optimal delivery of immunotherapy in advanced NSCLC

Written by | 11 Nov 2019

Immunotherapy has been hailed as a “game changer” in the treatment of lung cancer. As experience and understanding grows, optimal ways of delivering this type of treatment are… read more.

Immunotherapy – where are we now?

Written by | 11 Nov 2019

Immunotherapy now has an established place in treatment of non-small cell lung cancer but many questions remain such as the role of tumour mutational burden as a biomarker… read more.

Highlights from WCLC 2019

Written by | 21 Oct 2019

The IASLC WCLC meeting, held in Barcelona this year, covered many interesting topics and reported data from clinical trials relevant to the management of lung cancer. In the… read more.

Lung cancer screening and its implications

Written by | 19 Jul 2019

Professor Bob Steele CBE (Dundee, UK) discusses the potential implementation of a National Screening Programme in the UK, and the view post-NELSON, as well as highlighting the next steps in… read more.

Translational oncology symposium

Written by | 18 Jul 2019

The use of tyrosine kinase inhibitors (TKIs) in the treatment of ALK-positive NSCLC is now well-established. Professor Ross Camidge (University of Colorado Cancer Centre, Denver, USA) described the lessons that… read more.

UK impact of trial data

Written by | 8 Jul 2019

Dr Fiona McDonald (London, UK) discusses radical treatment for oligo metastatic NSCLC and if it should be the standard of care and Professor James Spicer (London, UK), the session Chair,  gives… read more.

Translational oncology: Tumour mutational burden and exploitation of DNA repair

Written by | 5 Jul 2019

Professor Ahmed gives an overview of one of the sessions in the BTOG Translational Oncology Symposium.

PACIFIC and beyond – the promise of immunotherapy

Written by | 10 May 2019

Correvio Pharma has resubmitted a New Drug Application (NDA) to the US FDA seeking approval for Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF).

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.